The Drug Regulatory Authority of Pakistan (DRAP) has issued a ban on the sale of several batches of substandard medicines, including two cough syrups, after a laboratory test found them to be hazardous to public health.
According to the report, DRAP’s investigation revealed that eight batches of two cough syrup brands, Tussin DM Suspension and one batch of Arp Powder, were found to be substandard.
In addition, four batches of other medicines, including Metrovan Syrup, Ann-vil Injection, and seven batches of Torax and Zond Syrup, were also identified as substandard.
The laboratory tests showed that the Torax and Zond Syrups contained ethylene glycol levels exceeding safe limits, posing significant health risks to consumers.
DRAP immediately issued a recall alert for these hazardous drugs and implemented a ban on the sale of the affected batches to safeguard public health.
Read more
CM Gandapur takes over grid station, threatens to cut off electric supply from KP
Journalist killed in Khyber district laid to rest after protest
The decision comes after the Punjab Drug Control Directorate submitted initial samples of the suspect medicines to DRAP, leading to the comprehensive investigation and regulatory action.
DRAP has stressed the importance of consumer safety and urged the public to be vigilant when purchasing medicines.
The authority has assured that it will continue to closely monitor the pharmaceutical market and take swift action against any substandard or adulterated drugs to protect the health and well-being of the people of Pakistan.
